Results 1 to 10 of about 170,525 (342)

Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation [PDF]

Gastroenterology Insights, 2023
Hepatitis C infection is a leading etiology of hepatic dysfunction and a major indication for liver transplantation due to the development of fibrosis, cirrhosis, and hepatocellular carcinoma.
Sonia Samuel, Ahmad Abulawi, Raza Malik
doaj   +2 more sources

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Nature Network Boston, 2021
Aleksandra Deczkowska, Eyal David, Pierluigi Ramadori, Dominik Pfister, Michal Safran, Baoguo Li, Amir Giladi, Diego Adhemar Jaitin, Oren Barboy, Merav Cohen, Ido Yofe, Chamutal Gur, Shir Shlomi-Loubaton, Sandrine Henri, Suhail Yousuf, Mengjie Qiu, Shing Kam, Hila Hermon, Eylon Lahat, Gil Ben Yakov, Oranit Cohen‐Ezra, Yana Davidov, Mariya Likhter, David Goitein, Susanne Roth, Achim Weber, Bernard Malissen, Assaf Weiner, Ziv Ben‐Ari, Mathias Heikenwälder, Eran Elinav, Ido Amit   +31 more
openalex   +3 more sources

P-80 SEVERELY OBESE PATIENTS HAD HEPATIC FIBROSIS EVEN WITHOUT METABOLIC SYNDROME

Annals of Hepatology, 2021
Introduction: Metabolic Associated Fatty Liver Disease (MAFLD) is a clinic-pathological condition commonly associated with metabolic syndrome (MS) and this association is frequently found in severely obese. Objective: To compare clinical and histological
Carla Daltro, Ana Paula Berbeth-Casto, Luiz Antonio R de-Freitas, Antônio Ricardo Andrade, Helma P. Cotrim   +4 more
doaj   +1 more source

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, 2023
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.
Z. Younossi, P. Golabi, James M. Paik, Austin Henry, Catherine Van Dongen, L. Henry   +5 more
semanticscholar   +1 more source

O-22 METABOLIC ASSOCIATED FATTY LIVER DISEASE: A SEVERE LIVER DISEASE

Annals of Hepatology, 2021
Background: The spectrum of metabolic associated fatty liver disease (MAFLD) includes steatosis, steatohepatitis, that can progress to cirrhosis, hepatocellular carcinoma, and to advanced stage of liver disease.
Ana Rafaela S. Do Vale, Andreza Rosa Cabral, Naiade S. Almeida, Antonio Ricardo C.F. Andrade, Ana Cristina Landim, Helma P. Cotrim   +5 more
doaj   +1 more source

O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT?

Annals of Hepatology, 2021
Background: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest.
Andreza Rosa Cabral, Ana Rafaela S. Do Vale, Naiades S. Almeida, Raquel Rocha, Antonio Ricardo C.F. de Andrade, Ana Cristina Landin, Helma P. Cotrim   +6 more
doaj   +1 more source

P-83 RELEVANCE OF RENAL CHANGES IN A LARGE SERIES OF SEVERELY OBESE PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE

Annals of Hepatology, 2021
Introduction: Metabolic associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. Recently, the relationship between MAFLD and chronic kidney disease has raised more interest because this relationship may be an ...
Kellyane Dias Carvalho, Carla Daltro, Claudia Daltro, Helma P. Cotrim   +3 more
doaj   +1 more source

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

Nature Network Boston, 2023
The FLIGHT-FXR trial, testing farnesoid X receptor agonist tropifexor in nonalcoholic steatohepatitis, demonstrated sustained decreases in alanine aminotransferase levels and hepatic fat fraction, but not aspartate aminotransferase, with dose-dependent ...
A. Sanyal, Patricia Lopez, E. Lawitz, K. Lucas, J. Loeffler, Won Kim, G. Goh, Jee‐Fu Huang, C. Serra, P. Andreone, Yi-Cheng Chen, S. Hsia, V. Ratziu, D. Aizenberg, Hiroshi Tobita, A. Sheikh, J. Vierling, Y. Kim, H. Hyogo, Dean Tai, Z. Goodman, F. Schaefer, I. R. Carbarns, S. Lamle, M. Martic, N. Naoumov, C. Brass   +26 more
semanticscholar   +1 more source

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies

Cells, 2021
5′AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio. The heterotrimeric AMPK protein comprises three subunits, each
Christian von Loeffelholz, Sina M. Coldewey, Andreas L. Birkenfeld   +2 more
doaj   +1 more source

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol

Nature Communications, 2023
The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis.
Ming Yang, Xiaoqiang Qi, Nan Li, J. Kaifi, Shiyou Chen, Andrew A. Wheeler, E. Kimchi, A. Ericsson, R. Scott Rector, K. Staveley-O’Carroll, Guangfu Li   +10 more
semanticscholar   +1 more source